Research & Development
Pathology & AI
Biomarker Discovery & Validation
AriBio, Fujirebio partner on biomarker development for Alzheimer’s, other neurodegenerative disorders
The agreement will provide Fujirebio access to clinical samples and data that have been collected in an ongoing phase III Alzheimer’s disease study being conducted by AriBio.
March 8, 2023
Protein expression biomarker may identify likely responders to potential breast cancer drug
In a study, researchers sought to understand the value of RANK and RANKL protein expression as a predictor of breast cancer outcomes and as a therapeutic target.
March 8, 2023
ApoB testing may reveal patients at risk of heart disease missed by cholesterol tests: study
In the study, investigators looked at electronic medical records for patients who had ApoB and standard lipid profiles tested within 90 days of each other from 2010 to early 2022.
March 6, 2023
Biocare Medical acquires Empire Genomics to expand molecular biomarker portfolio
The acquisition of Empire Genomics will expand Biocare Medical’s molecular biomarker portfolio substantially.
November 22, 2022
Universal Diagnostics study assesses methylation biomarkers' role in early colorectal cancer
The company will present the findings at the AACR Special Conference on Precisions, Prevention, Early Detection, and Interception of Cancer being held in Austin, TX, November 17-19.
November 17, 2022
Mainz Biomed initiates U.S. extension of colorectal cancer study to evaluate mRNA biomarkers
Mainz Biomed announced an extension of its ColoFuture European study, which aims to evaluate the use of mRNA biomarkers for the early detection of colorectal cancer.
November 15, 2022
Quest launches long-COVID testing panels for consumers
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for millions of dollars in unnecessary urinalysis testing
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
LumiraDx Q4 revenues drop 65% on lower COVID-19 testing
Patients prefer immediate test results, even when the news is bad
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Akoya Biosciences launches panels for spatial biomarker discovery and validation
The PhenoCode Signature Panels are a hybrid of the company’s legacy Codex and Opal assays, and, when combined with the PhenoImager platforms, enable spatial phenotyping workflow, Akoya said.
November 8, 2022
QMC Health, Lawson Health Research ink agreement for long-COVID blood biomarkers
With blood biomarkers acquired in an agreement with Lawson Health Research Institute, QMC Health plans to develop a point-of-care rapid test using its QDX HPFIS technology.
November 1, 2022
Quest Diagnostics, Decode Health expand collaboration on biomarker discovery to MS, NAFLD
At this stage of the collaboration, the companies will focus on early detection, differential diagnosis, and therapy selection for multiple sclerosis (MS) and nonalcoholic fatty liver disease (NAFLD).
October 18, 2022
Renalytix to present at American Society of Nephrology Kidney Week
The presentations will include a cost-effectiveness analysis supporting population-based KidneyIntelX testing for Medicare patients, as well as findings from a multiyear study at a major healthcare system highlighting disparities in healthcare access.
October 17, 2022
Oni, University of Pennsylvania to collaborate on CAR-T therapy research
Oni's Nanoimager super-resolution microscopy will allow researchers to visualize living cells and observe how single molecules interact.
October 11, 2022
Bio-Techne releases automated codetection assays for Roche platform
Developed in partnership with Roche, the new automated multiomic assays use Bio-Techne's patented RNAscope and BaseScope signal amplification and background suppression technologies.
October 6, 2022
Page 1 of 3